Virpax Pharmaceuticals Reports 2024 Second Quarter Results and Recent DevelopmentsBusiness Wire • 08/13/24
Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference August 14-15Business Wire • 08/08/24
Pain Management-Focused Penny Stock Virpax Pharmaceuticals Surges Over 100% On Wednesday-Here's Why?Benzinga • 07/10/24
Virpax Pharmaceuticals Secures $2.5 Million Loan Financing and an Agreement with an Institutional Investor to Negotiate Additional FundingBusiness Wire • 07/08/24
Virpax Pharmaceuticals Reports 2024 First Quarter Results and Recent DevelopmentsBusiness Wire • 05/13/24
Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid PriceBusiness Wire • 02/27/24
Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.Business Wire • 02/27/24
Virpax Pharmaceuticals Announces Preliminary Results of ProbudurTM Pilot Study with the U.S. Army Institute of Surgical ResearchBusiness Wire • 02/07/24
Virpax Pharmaceuticals Announces Notification from Nasdaq Related to Delayed Form 10-Q FilingBusiness Wire • 11/17/23
Virpax Pharmaceuticals Reports 2023 Third Quarter Results and Recent DevelopmentsBusiness Wire • 11/15/23
Virpax Pharmaceuticals Announces that Envelta™ Remains on Track for Trial in Humans Following FDA ReviewBusiness Wire • 10/31/23
Virpax Pharmaceuticals Announces Extension of CRADA with the U.S. Army Institute of Surgical ResearchBusiness Wire • 10/12/23